Success Metrics

Clinical Success Rate
97.8%

Based on 44 completed trials

Completion Rate
98%(44/45)
Active Trials
1(2%)
Results Posted
41%(18 trials)
Terminated
1(2%)

Phase Distribution

Ph not_applicable
10
18%
Ph phase_3
14
25%
Ph phase_1
3
5%
Ph phase_2
18
32%
Ph phase_4
11
20%

Phase Distribution

3

Early Stage

18

Mid Stage

25

Late Stage

Phase Distribution56 total trials
Phase 1Safety & dosage
3(5.4%)
Phase 2Efficacy & side effects
18(32.1%)
Phase 3Large-scale testing
14(25.0%)
Phase 4Post-market surveillance
11(19.6%)
N/ANon-phased studies
10(17.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.7%

44 of 46 finished

Non-Completion Rate

4.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

56

all time

Status Distribution
Active(2)
Completed(44)
Terminated(2)
Other(8)

Detailed Status

Completed44
unknown8
Withdrawn1
Active, not recruiting1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
56
Active
1
Success Rate
97.8%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (5.4%)
Phase 218 (32.1%)
Phase 314 (25.0%)
Phase 411 (19.6%)
N/A10 (17.9%)

Trials by Status

unknown814%
withdrawn12%
active_not_recruiting12%
completed4479%
not_yet_recruiting12%
terminated12%

Recent Activity

Clinical Trials (56)

Showing 20 of 56 trialsScroll for more
NCT03817970Phase 3

Cisplatin Disposition and Kidney Injury

Active Not Recruiting
NCT05956899Phase 4

Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients

Completed
NCT03204279Phase 2

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

Completed
NCT04308837Phase 2

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Unknown
NCT03040726Phase 2

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Completed
NCT05841849Phase 4

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Not Yet Recruiting
NCT03674294Phase 3

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

Completed
NCT04585412Phase 4

Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)

Completed
NCT04912271Phase 3

Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

Unknown
NCT00967499Phase 2

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

Completed
NCT02135510Phase 3

MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy

Completed
NCT04060771Phase 3

Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery

Unknown
NCT03960151Phase 2

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Withdrawn
NCT03586817Phase 4

PALONOSETRON X FOSAPREPITANT IN PONV

Unknown
NCT02625181Not Applicable

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed
NCT02941913Phase 4

Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients

Completed
NCT03606369Phase 2

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

Unknown
NCT02557035Phase 3

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting

Completed
NCT02744508Not Applicable

Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery

Completed
NCT02480088Phase 4

Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism

Completed

Drug Details

Intervention Type
DRUG
Total Trials
56